propranolol has been researched along with Primary Peritonitis in 27 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It has been suggested that propranolol may have a protective effect on the development of spontaneous bacterial peritonitis by increasing the motility of the bowel and lowering the pressure of the portal vein." | 7.73 | Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? ( Archimandritis, AJ; Burroughs, AK; Cholongitas, E; Manesis, EK; Papatheodoridis, GV, 2006) |
| "Sclerosing peritonitis developed in a 56-year-old white man who had been receiving propranolol (320 mg/day) for hypertension and angina pectoris since December 1976." | 7.66 | Sclerosing peritonitis and propranolol. ( Ahmad, S, 1981) |
| "Sclerosing peritonitis developed in a 43-year-old man with angina pectoris who had been receiving the beta-adrenergic receptor antagonist, propranolol." | 7.66 | Sclerosing peritonitis and propranolol. ( Harty, RF, 1978) |
| "We assessed the impact of propranolol on death, risk of hepatorenal syndrome and peritonitis in patients with cirrhosis." | 3.83 | Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. ( Bang, UC; Bendtsen, F; Benfield, T; Hyldstrup, L; Jensen, JE, 2016) |
| "It has been suggested that propranolol may have a protective effect on the development of spontaneous bacterial peritonitis by increasing the motility of the bowel and lowering the pressure of the portal vein." | 3.73 | Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? ( Archimandritis, AJ; Burroughs, AK; Cholongitas, E; Manesis, EK; Papatheodoridis, GV, 2006) |
| "Sclerosing peritonitis developed in a 56-year-old white man who had been receiving propranolol (320 mg/day) for hypertension and angina pectoris since December 1976." | 3.66 | Sclerosing peritonitis and propranolol. ( Ahmad, S, 1981) |
| "Sclerosing peritonitis developed in a 43-year-old man with angina pectoris who had been receiving the beta-adrenergic receptor antagonist, propranolol." | 3.66 | Sclerosing peritonitis and propranolol. ( Harty, RF, 1978) |
| "We studied the effects of alcohol and propranolol on the course of peritonitis in rabbits." | 3.66 | Propranolol antagonizes the anti-inflammatory effect of alcohol and improves survival of infected intoxicated rabbits. ( Buckley, RM; MacGregor, RR; Ventura, ES, 1978) |
| "Bacterial infections have been hypothetized to be a trigger of variceal bleeding in cirrhotic patients and beta-blockers may have a protective effect by decreasing bacterial translocation, reducing portal pressure." | 2.45 | beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. ( Burra, P; Burroughs, AK; Cholongitas, E; Leandro, G; Patch, D; Senzolo, M; Thalheimer, U, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (55.56) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, UC | 1 |
| Benfield, T | 1 |
| Hyldstrup, L | 1 |
| Jensen, JE | 1 |
| Bendtsen, F | 1 |
| Senzolo, M | 3 |
| Cholongitas, E | 3 |
| Burra, P | 1 |
| Leandro, G | 1 |
| Thalheimer, U | 1 |
| Patch, D | 1 |
| Burroughs, AK | 4 |
| Kalra, S | 1 |
| Atia, A | 1 |
| McKinney, J | 1 |
| Borthwick, TR | 1 |
| Smalligan, RD | 1 |
| Fries, W | 1 |
| Buda, A | 1 |
| Pizzuti, D | 1 |
| Nadal, E | 2 |
| Sturniolo, GC | 1 |
| D'Incà, R | 1 |
| Wong, F | 1 |
| Salerno, F | 1 |
| Angeli, P | 1 |
| Abraldes, JG | 1 |
| Tarantino, I | 1 |
| Turnes, J | 1 |
| Garcia-Pagan, JC | 1 |
| Rodés, J | 1 |
| Bosch, J | 1 |
| Soylu, AR | 1 |
| Dökmeci, G | 1 |
| Tezel, A | 1 |
| Amuca, H | 1 |
| Umit, H | 1 |
| Papatheodoridis, GV | 1 |
| Manesis, EK | 1 |
| Archimandritis, AJ | 1 |
| Youn, KH | 1 |
| Kim, DJ | 1 |
| Landman, MD | 1 |
| Longmire, WP | 1 |
| Nicholls, JT | 1 |
| Rutty, DA | 1 |
| Ing, TS | 1 |
| Daugirdas, JT | 1 |
| Gandhi, VC | 1 |
| Marigold, JH | 1 |
| Pounder, RE | 1 |
| Pemberton, J | 1 |
| Thompson, RP | 2 |
| Ahmad, S | 1 |
| Frishman, W | 1 |
| Silverman, R | 1 |
| Strom, J | 1 |
| Elkayam, U | 1 |
| Sonnenblick, E | 1 |
| Harty, RF | 1 |
| Buckley, RM | 1 |
| Ventura, ES | 1 |
| MacGregor, RR | 1 |
| Benny, PS | 1 |
| Denham, HE | 1 |
| Panting, AL | 1 |
| Jackson, BT | 1 |
| Gurry, JF | 1 |
| Cunningham, IG | 1 |
| Brooke, BN | 1 |
| Riabrsev, VG | 1 |
| Iarema, IV | 1 |
| Dzheĭranov, FD | 1 |
| Mezvrishvili, GO | 1 |
| Fil'chev, MI | 1 |
| Sjöqvist, A | 1 |
| Hallerbäck, B | 1 |
| Glise, H | 1 |
| Chepkiĭ, LP | 1 |
| Pys'ko, SA | 1 |
| Shemchuk, AS | 1 |
| Kandel, G | 1 |
| Diamant, NE | 1 |
| Holzer, P | 1 |
| Lippe, IT | 1 |
| Holzer-Petsche, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study[NCT02123576] | 12 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Poor enrollment of study population) | |||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02123576)
Timeframe: baseline and 14 days
| Intervention | g/dL (Mean) |
|---|---|
| Treatment | 0.48 |
| Placebo | 0.03 |
Defined as creatinine level above baseline value after day 7, dialysis or death (NCT02123576)
Timeframe: up to day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 3 |
| Placebo | 3 |
We define as serum creatinine level decreased by >50% from baseline but not to <1.5 mg/dL, without dialysis or HRS recurrence (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 2 |
We define this as a decrease in serum creatinine level to <1.5 mg/dL without dialysis or death (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 1 |
This will be the combination of transplant free survival and those patients who received liver transplant (NCT02123576)
Timeframe: up to 1 year
| Intervention | days (Mean) |
|---|---|
| Treatment | 102 |
| Placebo | 59 |
(NCT02123576)
Timeframe: day 30 and 180
| Intervention | days (Mean) |
|---|---|
| Treatment | 80 |
| Placebo | 36 |
3 reviews available for propranolol and Primary Peritonitis
| Article | Year |
|---|---|
beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Bacterial Infections; Bacterial Translocation; Databases, Bibliographic | 2009 |
Sclerosing encapsulating peritonitis associated with propranolol usage: a case report and review of the literature.
Topics: Adrenergic beta-Antagonists; Humans; Intestinal Obstruction; Male; Middle Aged; Peritonitis; Propran | 2009 |
A clinical view of recent advances in ascites.
Topics: Animals; Ascites; Ascitic Fluid; Bacterial Infections; Blood Volume; Body Water; Extracellular Space | 1986 |
24 other studies available for propranolol and Primary Peritonitis
| Article | Year |
|---|---|
Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers.
Topics: Aged; Cause of Death; Databases, Factual; Denmark; Dose-Response Relationship, Drug; Female; Hepator | 2016 |
Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding?
Topics: Adrenergic beta-Antagonists; Bacterial Translocation; Clinical Trials as Topic; Esophageal and Gastr | 2009 |
Beta-blockers in cirrhosis: friend and foe?
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Humans; Liver Cirrhosis; Peritonitis; P | 2010 |
β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists.
Topics: Adrenergic beta-Antagonists; Ascites; Bacterial Infections; Cardiovascular Diseases; Female; Hepator | 2011 |
Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis?
Topics: Adrenergic beta-Antagonists; Aged; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, | 2011 |
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Topics: Antihypertensive Agents; Ascites; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; F | 2003 |
Propranolol does not affect incidence of spontaneous bacterial peritonitis in cirrhotic patients with ascites.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Ascites; Bacterial Translocation; Esophageal and Gastric V | 2003 |
Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Ascitic Fluid; Bacterial Infections; Chi-Square Distribu | 2006 |
[Prevention of variceal bleeding and measurement of hepatic vein pressure gradient].
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Esophageal and Gastric Varices; Gastrointest | 2006 |
Neural and hormonal influences of peritonitis on paralytic ileus.
Topics: Animals; Dogs; Epinephrine; Gastrointestinal Motility; Intestinal Obstruction; Iodine; Kymography; P | 1967 |
Sclerosing peritonitis with short-term propranolol therapy.
Topics: Drug Eruptions; Eye Diseases; Humans; Peritonitis; Propranolol; Sclerosis | 1980 |
Peritoneal sclerosis in peritoneal dialysis patients.
Topics: Adult; Humans; Male; Peritoneal Dialysis; Peritoneum; Peritonitis; Propranolol; Sclerosis | 1984 |
Propranolol, oxprenolol, and sclerosing peritonitis.
Topics: Adult; Aged; Female; Humans; Intestine, Small; Male; Middle Aged; Oxprenolol; Peritoneum; Peritoniti | 1982 |
Sclerosing peritonitis and propranolol.
Topics: Angina Pectoris; Colon; Gastrointestinal Hemorrhage; Humans; Hypertension; Male; Middle Aged; Perito | 1981 |
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Bronchi; Central Nervous System Diseases; Deafnes | 1979 |
Sclerosing peritonitis and propranolol.
Topics: Adult; Conjunctivitis; Drug Eruptions; Humans; Male; Peritonitis; Propranolol; Sclerosis | 1978 |
Propranolol antagonizes the anti-inflammatory effect of alcohol and improves survival of infected intoxicated rabbits.
Topics: Alcoholic Intoxication; Animals; Anti-Inflammatory Agents; Cell Adhesion; Ethanol; Granulocytes; Hum | 1978 |
Letter: Practolol reaction.
Topics: Female; Humans; Intestinal Obstruction; Middle Aged; Peritonitis; Practolol; Propranolol; Sclerosis | 1975 |
Letter: Beta-blockers and fibrinous peritonitis.
Topics: Humans; Peritonitis; Practolol; Propranolol | 1975 |
Letter: beta-blockers and fibrinous peritonitis.
Topics: Aged; Angina Pectoris; Female; Humans; Intestinal Obstruction; Peritonitis; Pleural Effusion; Practo | 1975 |
[Hemosorption and endolymphatic therapy in the treatment of paralytic ileus in peritonitis and acute intestinal obstruction].
Topics: Acute Disease; Aged; Female; Gastrointestinal Motility; Hemoperfusion; Humans; Injections, Intralymp | 1990 |
Reflex adrenergic inhibition of colonic motility in anesthetized rat caused by nociceptive stimuli of peritoneum. An alpha 2-adrenoceptor-mediated response.
Topics: Animals; Blood Pressure; Colon; Female; Gastrointestinal Motility; Heart Rate; Isoproterenol; Male; | 1985 |
[Use of obsidan and potassium phosphate for correction of the oxygen transport function of the blood in peritonitis].
Topics: Adolescent; Adult; Aged; Child; Drug Therapy, Combination; Humans; Infusions, Intravenous; Middle Ag | 1987 |
Inhibition of gastrointestinal transit due to surgical trauma or peritoneal irritation is reduced in capsaicin-treated rats.
Topics: Animals; Animals, Newborn; Capsaicin; Gastrointestinal Motility; Intestinal Obstruction; Intestines; | 1986 |